Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Antigen Peptide CD22 HLA- A*0201 (QLQWLLEGV) 1 mg

Antigen Peptide CD22 HLA- A*0201 (QLQWLLEGV) US$178.10 Excluding tax and shipping fees In stock Description About Antigen Peptide CD22 HLA- A*0201 (QLQWLLEGV) The Human B-cell receptor CD22 Peptide is a high quality epitope peptide for stimulation of antigen-s

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Antigen Peptide CD22 HLA- A*0201 (QLQWLLEGV)

US$178.10

Excluding tax and shipping fees

In stock

Description

About Antigen Peptide CD22 HLA- A*0201 (QLQWLLEGV)

The Human B-cell receptor CD22 Peptide is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The B-cell receptor CD22 Peptide, H-QLQWLLEGV-OH (Uniprot: P20273 aa: 173-181) from JPT is produced under strict quality control and quality management.

Antigen Peptide CD22 HLA- A*0201 (QLQWLLEGV) - Specifications

Peptide sequence: H-QLQWLLEGV-OH

Amount: 1 mg

Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)

Delivery Format: Freeze-dried in plastic vial

Application(s): T-cell immunity

Condition(s)/Topic(s): Cancer

Standard Delivery Time: approx. 10 days

Your Custom or Scrambled Antigen Peptide!

Do you need a scrambled version of this antigen peptide?We can produce scrambled versions for all our antigen peptides and other peptide sequences. These scrambled peptide versions are cross-checked against the Uniprot database to ensure that the scrambled sequence does not correspond to any natural sequence. Have a look at Scrambled Antigen Peptides!

Are you interested in other antigen peptides?Choose sequence, amount and purity. We will assist you along the way: Custom Peptide Synthesis

JPT’s Antigen PeptidesFind your antigen peptide and select the connected PepMix™ Peptide Pool and MHC Multimer for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.

Benefits of JPT’s Antigen Peptides- All peptides are made in Germany- Bulk orders or custom peptide snythesis upon request- Synthesis protocols designed to avoid toxic contaminants and side products - Provision of freeze dried aliquots for enhanced stability - Proven track record for applications in clinical studies- Order the connected PepMix™ Peptide Pool with your peptide!

References

References for Antigen Peptide CD22 HLA- A*0201 (QLQWLLEGV)

References:Read References with Antigen Peptides

Documentation

Documentation for Antigen Peptide CD22 HLA- A*0201 (QLQWLLEGV)

Protocol_PepMix.pdf

CD22-QLQWLLEGV-2.pdf

Properties

Properties of Antigen Peptide CD22 HLA- A*0201 (QLQWLLEGV)

T-cell immunity

Antigen Peptides

Cancer

Freeze-dried in plastic vial

Human

B-cell receptor CD22

Trial Grade: each peptide purified to > 90% (HPLC/MS)

No

Further Information to Antigen Peptide CD22 HLA- A*0201 (QLQWLLEGV)

Values

H-QLQWLLEGV-OH

9mer peptide as TFA salt

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Is this peptide right for your research?

This peptide is typically selected when working with HLA-A*24:02 or HLA-A*23:01-restricted systems and when a broader representation of CMV-specific responses is required beyond the most dominant A*02:01 epitopes. It is particularly useful in studies involving diverse donor cohorts or population-level immune profiling. It is less suitable if your experimental setup is optimized around HLA-A*02:01-restricted readouts or relies on highly immunodominant reference peptides such as NLVPMVATV. In those cases, alternative pp65-derived sequences may provide stronger or more consistent responses.

Source: jpt.com ↗

Custom Peptide Synthesis for HBV Protein Research

At JPT Peptide Technologies, we offer extensive customization options for HBV protein peptides to fit your specific research needs: Custom Sequences: Tailor your HBV peptide sequence to match your experimental requirements. Varied Quantities: Choose from micro-scale to larger quantities based on your research scale. Purity Levels: Select from different purity grades to ensure optimal performance in your assays.

Source: jpt.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides

04
Peptide Therapy Guide Editorial Team

Antigen Peptide LMP2 HLA-A*2402 (PYLFWLAAI) 10 mg

EBV LMP2 131-139 Peptide (HLA-A*24:02) - PYLFWLAAI US$533.00 Excluding tax and shipping fees In stock Description About EBV LMP2 131-139 Peptide (HLA-A*24:02) - PYLFWLAAI The Epstein-Barr Virus (EBV) Latent me…

Read guide →